Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Informazioni relative al progetto

SHIGETECVAX

ID dell’accordo di sovvenzione: 815568

DOI 10.3030/815568

Data della firma CE 30 Aprile 2019

Data di avvio 1 Settembre 2019

Data di completamento 28 Febbraio 2025

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale € 0,00

Contributo UE € 8 603 989,93

Coordinato da

EUROPEAN VACCINE INITIATIVE E.V
Germany

Risultati finali

Open Research Data Pilot (1)

ORPD: Open Research Data Pilot

tbc

Documents, reports (1)

Composition of the SEAC incl. an ethics advisor

Composition of the SEAC incl an ethics advisor

Websites, patent fillings, videos etc. (1)

SHIGETECVAX web site

SHIGETECVAX web site established and launched

Pubblicazioni

Peer reviewed articles (1)

Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial

Autori: Girardi, Petra, Shushan Harutyunyan, Irene Neuhauser, Katharina Glaninger, Orsolya Korda, Gábor Nagy, Eszter Nagy, Valéria Szijártó, Denes Pall, Krisztina Szarka, Gábor Kardos, Tamás Henics, and Frank J. Malinoski
Pubblicato in: Vaccines, 2022, ISSN 2076-393X
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines10020340